
    
      This study will test effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant
      therapy in type 1 diabetes (TID) Subjects on metabolic control in this population. Insulin
      sensitivity, glucose control (variability) and triglycerides will be measured after 8 weeks
      of treatment and compared to baseline.
    
  